Two novel inhibitors of aflatoxin production by Aspergillus parasiticus were isolated from the mycelial extracts of Streptomyces sp. MRI142 and termed aflastatin A and B. The structures of aflastatin A (1) and B (5) were elucidated by NMR and chemical degradation experiments. These compounds have a novel skeleton of a tetramic acid derivative with a highly oxygenated long alkyl chain. The incorporation experiments using 13C -labeled acetates , propionate, glucose and glycolate suggested that most of the C2 and C3 units involved in the alkyl chain moiety of aflastatin A were biosynthesized from acetic and propionic acids, but five C2 units in the alkyl chain originated from glycolic acid.
Two novel inhibitors of aflatoxin production by Aspergillus parasiticus were isolated from the mycelial extracts of Streptomyces sp. MRI142 and termed aflastatin A and B. The structures of aflastatin A (1) and B (5) were elucidated by NMR and chemical degradation experiments. These compounds have a novel skeleton of a tetramic acid derivative with a highly oxygenated long alkyl chain. The incorporation experiments using 13C -labeled acetates , propionate, glucose and glycolate suggested that most of the C2 and C3 units involved in the alkyl chain moiety of aflastatin A were biosynthesized from acetic and propionic acids, but five C2 units in the alkyl chain originated from glycolic acid.
Aflatoxin is a most potent environmental carcinogen. It is produced by some strains of Aspergillus flavus, A. parasiticus and A. nomius. Since discovery of the potent carcinogenicity of aflatoxin in the 1960s and subsequent detection of the toxin in a wide variety of food commodities, control and management of this toxin have been issues of concern1). To protect foods and feeds from aflatoxin contamination, growth inhibitors of aflatoxigenic fungi are useful. However, effective fungicides are usually toxic to mammals to some extent and may provoke the emergence and pervasion of resistant strains as in the cases of many other drug-resistant microorganisms. On the other hand, it is known that the production of aflatoxin is not essential for the growth of its producing strain.
Therefore, a specific inhibitor of aflatoxin biosynthesis may be a good candidate for a drug to depress aflatoxin contamination, which may not select the resistant strain and minimize the risk of pervasion of drug-resistant strains.
Until now, many substances have been screened for prevention of aflatoxin contamination in foods and feeds. 2) Among them, organo-phosphorous insecticides with choline esterase inhibitory activity, such as dichlorvos, were found to show unique inhibitory effects on aflatoxin production. They inhibit some esterases involved in the biosynthetic pathway of aflatoxin to result in the inhibition of aflatoxin biosynthesis.3) Some inhibitors of pentaketide-derived melanin biosynthesis in fungi, such as tricyclazole and chlorobenthiazone, were recently shown to have an inhibitory activity against aflatoxin production in A. flavus. They are presumed to inhibit a reductase in the biosynthetic pathway of aflatoxin.4,5) To obtain a new specific inhibitor of aflatoxin production, we have continued on screening of metabolites from microorganisms using a system of A.
parasiticus and aflatoxin-sensitive bacteria. During the course of screening, Streptomyces sp. MRI142 was found to produce strong inhibitors, termed aflastatins, which inhibit aflatoxin production without essentially affecting the growth of its producer. We have already reported the isolation and preliminary elucidation of the structure and biosynthesis of the major component, aflastatin A.6,7) This paper describes the detailed structural elucidation of aflastatin A and further investigation of its biosynthesis, and the isolation, structure and biological activity of aflastatin B. 
Results and Discussion
Structural Elucidation of Aflastatin A Aflastatin A (1) was isolated as a white powder after lyophilization. The pseudomolecular ions of (M+Na)+ and (M-H)-were observed at m/z 1280 and 1256 in the positive and negative FAB-MS spectra of 1, respectively. The HR-FABMS spectrum of 1 and elemental analysis strongly suggested that the molecular formula of 1 was C62H115NO24, which was unambiguously confirmed after completing analysis of NMR spectra of 1 as later mentioned. The UV spectrum of 1 was very characteristic, which showed a shift from the absorption maxima at 299 and 247nm in neutral and basic solutions to those at 314 and 237nm in acidic solution, respectively.
The IR and 1H NMR spectra of 1 in DMSO-d6 solution suggested that 1 contains a number of hydroxyl groups in its molecule. The NMR signals of the carbons involved in the chromophore moiety of 1 were not clearly observed because of signal broadening when measured with free acid of 1, but they became detectable when the 13C NMR spectrum was measured with diethylamine salt of 1. By analyzing the DQF-COSY, DQF-relayed COSY, HMQC and HMBC spectra of 1, which were measured using diethylamine salt of 1 in DMSO-d6 solution, the presence of the partial structure (A) was clarified (Fig. 2) . The structure A was highly oxygenated, and the presence of the seven hydroxyl groups in it was verified from the COSY and HMBC spectra of 1 as shown in Figure 2 .
Other small partial structures were also identified from the various spectra above mentioned, but it was difficult to determine the total structure of 1 by further NMR analysis with the intact molecule. Since the partial structure (A) having several diol moieties was obtained, oxidation of 1 with NaIO4 was carried out to obtain fragment molecules in order to identify the remainder of the structure (Fig. 3) . First, 1 was oxidized with NaIO4, and followed by NaBH4 reduction and acetylation. The crude products obtained were purified by Sephadex LH-20 column chromatography and reverse-phase HPLC to afford two main products, 2 and 3 (Fig. 4) . The structure of a fragment was determined as 2 by analysis of its MS and NMR spectra. Another fragment had no characteristic absorption in its UV spectrum, and the molecular formula was determined as C44H70O20 by its HR-FABMS spectrum. Figure  5 , which determined the structure of the fragment as 3. Next, to obtain a fragment molecule containing the chromophoric moiety of 1, 1 was oxidized with NaIO4, and followed only by NaBH4 reduction.
In this case, after purification of the crude products by reverse-phase HPLC under basic conditions, the fragment 4, whose UV spectrum showed the same absorp- C-27 observed in a HMBC experiment, could determine the direction of linkage between 3 and structure A. From the above results, a large partial structure (B) containing all the carbon atoms of 1 was clarified (Fig.  3 ). This structure and molecular formula of 1 indicated that the only remaining problem was the position of an ether linkage. The formation of a tetrahydropyran ring by the ether linkage between C-33 and C-37 was revealed by the J values and NOEs around the ring protons as shown in Figure 7 . Thus, the total structure of aflastatin A was determined as 1. The assignments of protons and carbons in the NMR spectra of 1 are summarized in Table 1 . Table 1 , which were assigned based on the assignment of 1.
The biological activity of 5 toward the aflatoxigenic fungus, A. parasiticus NRRL2999, was examined, and the results are summarized in a Peak height ratio of 13C enriched to natural abundance . bIn 1 from [U-13C6]glucose. c,dCan not be determined due to signal overlappings or ambiguous assignments. No enrichment was observed. eCan not be determined due to ambiguous assignments, but three of them were clearly enriched. fNot detected. gCan not be determined due to signal overlappings or ambiguous assignments. hCan not be determined due to signal overlappings or ambiguous assignments.
No enrichment was observed. iCan not be determined due to signal overlappings. values deduced from the spectra are listed in Table 3 Other two 13C-13C couplings were also observed between C-4' and C-5', and C-5' and C-6', indicating that the C3 unit of C-4', 5', 6' originated from the glucose molecule.
Thus, it was easily presumed that the origin of the C3 unit should be alanine biosynthesized via pyruvate.
The results obtained suggested that a glycolic acid or its derivative might be incorporated into the C2 unit of Finally, a feeding experiment using [1-13C] glycolate was performed . In this case, a high level of 13C incorporation was not observed, but enrichment of C-7, 27, 29, 33 and 35 was clearly determined (Table 3) . From the above information, we may illustrate the biosynthetic origin of aflastatin A as summarized in Figure 8 . The origin of all carbon atoms of 1 except for the C1 unit at C-7' has been clarified. Culture method of Streptomyces sp. MRI142 for production of aflastatin A (1) and its isolation procedure have been reported previously.6) As aflastatin B (5) was isolated as a minor component of aflastatins produced by strain MRI142, its isolation procedure was the same as that of 1. Aflastatin B was precipitated from a tetrahydrofuran solution along with 1 as crude aflastatins. After the precipitate was washed with a solution of chloroform-methanol (2:1), the residue was purified by using HPLC on a C18 column (Capcell Pak Elution was carried out with methanol-0.5% diethylamine in water (62:38) and a flow rate of 7.0ml/minute at room temperature. Aflastatin B was eluted earlier than 1 from the HPLC column. The retention times of 1 and 5 were 18.8 and 16.1 minutes, respectively. Because of poor solubility of aflastatins in the mobile phase, this HPLC was repeated to obtain crude 5, in which a small amount of 1 was contaminated. Rechromatography of the crude 5 under the same conditions, followed by lyophilization, gave 5.7mg of 5 from 4.3 liters of culture broth. This yield was much smaller than that of 1 (500 mg from the same culture broth). A solution of NaIO4 (340mg) in water (8ml) was mixed with a solution of aflastatin A (250mg) in methanol (40ml). The solution was stirred for 5 hours and left for 19 hours at room temperature in the dark. After decomposing excess NaIO4 by adding a small amount of ethylenegylcol, NaBH4 (1.0g in 6ml of 0.1M NaOH) was added to the solution in an ice bath, which was stirred in an ice bath for 1 hour and then for 1 hour at room temperature. The reaction solution was neutralized with 3N HCl and concentrated. The residue obtained was extracted with methanol and the extract was concentrated. A mixture of acetic anhydride (2ml), pyridine (8ml) and 4-dimethylaminopyridine (10mg) was added to the residue, and the reaction mixture was stirred for 24 hours at room temperature, then was poured into water (140ml). After adjusting pH to 2.0 with conc. HCl, The ethyl acetate extract was washed with 5% NaHCO3 and concentrated to give a crude product (246mg), which was chromatographed on a Sephadex LH-20 column crude fragment 2 (50mg) was eluted from the column at the elution volume from 246ml to 308ml. After evaporating the methanol, the obtained residue was purified with preparative HPLC on a C18 column Tokyo). Elution was carried out with a linear gradient of methanol-0.1% diethylamine in water, starting with 35:65 to 60:40 for 40 minutes, then held 5 minutes, and a flow rate of 5.0ml/minute at room temperature. The peak at the retention time of 42.2 minutes afforded (CD3OD, 500MHz) 6.86 (dt, J=16, 7Hz, H-3), 5.78 (dt, (C-1), 149.7 (C-3), 124.0 (C-2), 33.1 (C-4), 33.1 (C-10), 30.7, 30.5, 30.4 and 30.3 (C-6, 7, 8, 9), 29.4 (C-5), 23.7 (C-11), 14.5 (C-12) .
To obtain fragment 3, a degradation experiment of 1 (250mg) was carried out again with the same procedure by which 2 was obtained. A crude fragment 3 (119mg) 70cm, MeOH) at the elution volume from 154ml to 209ml. Fragment 3 was purified with HPLC on the same column that 2 was purified. A solution of NaIO4 (340mg) in water (8ml) was mixed with a solution of aflastatin A (250mg) in methanol (40ml). The solution was stirred for 5 hours and left for 15 hours at room temperature in the dark. After decomposing excess NaIO4 by adding a small amount of ethyleneglycol, NaBH4 (670mg in 6ml of 0.1M NaOH) was added to the solution in an ice bath, which was stirred in an ice bath for 1 hour and then for 1 hour at room temperature. The pH of the reaction solution was adjusted to 6.0 with 2N HCl in an ice bath and concentrated. The obtained residue was extracted with methanol and the extract was concentrated, which was chromatographed on a Sephadex LH-20 column was eluted from the column at the elution volume from 176ml to 242ml. After evaporating the methanol, the obtained residue was purified with preparative HPLC on the same column that 2 was purified. 195 .5 (C-1), 175.8 (C-2'), 143.3 (C-3), 136.9 (C-2), 101.0 (C-3'), 61.8 (C-5'), 60.9 (C-8), 46.2 (C-5), 41.7 (C-7), 31.7 (C-4), 28.3 (C-6), 26.9 (C-7'), 21.1 (C-10), 20.4 (C-11), 16.3 (C-6'), 13.5 (C-9); HMBC correlations (nJCH=8Hz):
H-3 to C-1, 4, 5, 9 and 10, H-4 to C-2, 3 and 10, H-5 to C-3, 4, 6, 7, 10 and 11, H-7 to C-5, 6, 8 and 11, H-8 to C-7, H-9 to C-1, 2, and 3, H-10 to C-3, 4 and 5, H-11 to C-5, 6 and 7, H-5' to C-2', 4' and 6', H-6' to C-4' and 5', H-7' to C-2' and 5'. 
